132342-52-0

Basic information

• Product Name: (3aR,4R,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol
• Synonyms: (3aR,4R,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol;(1R,2S,3R,4R)-1-amino-2,3-(isopropyliden)dihydroxy-4-hydroxymethyl cyclopentane;4H-Cyclopenta-1,3-dioxole-4-methanol, 6-aminotetrahydro-2,2-dimethyl-, (3aR,4R,6R,6aS)-
• CAS NO: 132342-52-0
• Molecular Formula: C₉H₁₇NO₃
• Molecular Weight: 187.23618
• Mol File: 132342-52-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3aR,4R,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,4R,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol(132342-52-0)
• EPA Substance Registry System: (3aR,4R,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol(132342-52-0)

Safety Data

• Hazardous Substances Data: 132342-52-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Deoxyvasicinone is utilized as a compound of interest in pharmaceutical research due to its unique chemical structure and potential biological activity. Its cyclic nature and functional groups may contribute to its interaction with biological targets, offering opportunities for the development of new therapeutic agents.
Used in Drug Development:
In the field of drug development, deoxyvasicinone is employed as a starting point for the synthesis of novel compounds with potential therapeutic applications. Its unique structure and properties may be leveraged to design and optimize new drugs targeting specific diseases or conditions.
Used in Medicinal Chemistry:
Deoxyvasicinone serves as a valuable molecule in medicinal chemistry for the exploration of its structure-activity relationships. Understanding how its unique features contribute to biological activity can inform the design of more effective and selective drug candidates.
Used in Natural Product Chemistry:
As a naturally occurring compound, deoxyvasicinone is used in natural product chemistry to study the diversity of chemical structures found in nature. This can lead to the discovery of new bioactive compounds and insights into the biosynthetic pathways that produce them.

Upstream product

• 79200-57-0 (1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxylmethyl)-1-aminocyclopentan hydrochloride 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 24587-86-8 2',3'-isopropylidine (+/-) aristeromycin 
• 19186-33-5 aristeromycin 
• 174088-44-9 5-amino-1-(2',3'-O-isopropylidene-4'-hydroxymethylcyclopentyl)imidazole-4-benzyl carboxylate 
• 239080-22-9 C₄₈H₅₁N₇O₁₃ 
• 239080-22-9 5-[[(1R,2S,3R,4R)-2,3-(isopropylidenedioxy)-4-(hydroxymethyl)cyclopentyl]aminomethyleneamino]-1-[5-O-(monomethoxytrityl)-2,3-O-(isopropylidene)-β-D-ribofuranosyl]imidazole-4-(N-2,4-dinitrophenyl)carboxamide 
• 368870-22-8 9-benzyl-6-imino-1-[(1R,2S,3R,4R)-2,3-(isopropylidenedioxy)-4-(hydroxymethyl)cyclopentyl]purine 
• 368870-21-7 1-benzyl-4-cyano-5-[[(1R,2S,3R,4R)-2,3-(isopropylidenedioxy)-4-(hydroxymethyl)cyclopentyl]aminomethyleneamino]imidazole 
• 623547-33-1 8-chloro-N-1-[(1R,2S,3R,4R)-2,3-isopropylidenedioxy-4-(hydroxymethyl)cyclopentyl]-5'-O-[bis(phenylthio)phosphoryl]-2',3'-O-isopropylideneadenosine 
• 623547-31-9 8-chloro-N-1-[(1R,2S,3R,4R)-2,3-isopropylidenedioxy-4-[(5-monomethoxytrityl)oxymethyl]cyclopentyl]-2',3'-O-isopropylideneadenosine 
• 623547-30-8 8-chloro-N-1-[(1R,2S,3R,4R)-2,3-isopropylidenedioxy-4-[(5-monomethoxytrityl)oxymethyl]cyclopentyl]-5'-O-(tert-butyldimethylsilyl)-2',3'-O-isopropylideneadenosine 
• 623547-32-0 8-chloro-N-1-[(1R,2S,3R,4R)-2,3-isopropylidenedioxy-4-[(5-monomethoxytrityl)oxymethyl]cyclopentyl]-5'-O-[bis(phenylthio)phosphoryl]-2',3'-O-isopropylideneadenosine 
• 368870-28-4 N-1-[(1R,2S,3R,4R)-2,3-(isopropylidenedioxy)-4-(hydroxymethyl)cyclopentyl]-5'-O-[bis(phenylthio)phosphoryl]-2',3'-O-isopropylideneadenosine 
• 368870-26-2 N-1-[(1R,2S,3R,4R)-2,3-(isopropylidenedioxy)-4-[(4-monomethoxytrityl)oxymethyl]cyclopentyl]-2',3'-O-isopropylideneadenosine 
• 368870-25-1 N-1-[(1R,2S,3R,4R)-2,3-(isopropylidenedioxy)-4-[(4-monomethoxytrityl)oxymethyl]cyclopentyl]-5'-O-(tert-butyldimethylsilyl)-2',3'-O-isopropylideneadenosine 

Relevant articles and documents

CD73 INHIBITORS

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

CD73 INHIBITORS

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND

Disclosed is an antitumor effect potentiator for one or more other compounds having an antitumor effect, the antitumor effect potentiator comprising a novel pyrrolopyrimidine compound.

NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT

An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.

PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER

Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.

PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME

Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, XY, RY1, RY2 and RY3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.